Abdullah Al-Haqim 
A new study found that the new Alzheimer’s drug Donaneemab may cause brain bleeding in up to a third of patients.
Dunanimab (the US -driving in the name of Kisunla) was developed by Eli Lily, and obtained the approval of the US Food and Drug Administration on July 2. It is the most recent treatment in a new category of Alzheimer’s disease, which was widely praised in the media as “pioneering medications” and the first “modified treatments for the disease.”
All medications of this category produce anti -beta amyloid protein, a protein believed to cause disease, and share similar benefits and damage.
The new study – according to the British Daily Mail newspaper – conducted by the producing company of the drug itself, confirmed the results of the early studies that referred to the fatal risks of the drug.
Dangerous side effects
Scientists working at the pharmaceutical company Eli Lily found that at 3,000 patients who received the drug over a period of 3 years, the risk of a deadly condition that could cause serious bleeding and swelling. This condition is known as amyloid-related imaging abnormalities (ARIA), and occurs when the drug causes inflammation of the blood vessels in the brain.
Scientists have used data more than 3,000 patients with early Alzheimer’s disease, between 60 and 85 years old, who were given the drug over two separate experiences, each lasted 3 years.
For patients with the most dangerous cases of millicide, symptoms appeared in the first three months of taking the drug.
In October, the Medicine obtained the approval of the Medicines and Healthcare Products Regulatory Agency, which is the UK’s Drug Administration.
But health officials at the National Health Services Authority decided to ban it alongside another drug similar to Alzimer’s disease called LECANMAB, because the benefits of both are “very small” do not justify its cost on health services.
However, London’s private clinics have already started providing the drug with huge sums; One of the London clinics set the price of the drug to be 60,000 pounds annually (approximately 77 thousand dollars), and provided its first dose of Donnimab in January this year.
Doubts about the conflict of interests
George Perry, editor -in -chief of Alzheimer’s disease magazine, told the British Medical Magazine that new anti -amydid drugs, such as Adocanumab and Lycanimab, “all show an improper slowdown in dementia, in the midst of serious side effects, including death.”
Dunanimab, such as Alzheimer’s drug, which was previously approved, faces questions that are not only related to its effectiveness and the number of deaths among the patients who take it, but also the financial links between the members of the US Food and Drug Administration and pharmaceutical companies. The British Medical Journal found that 3 consultants recommended approval of the Donnimab drug, they received direct payments or research funding from its manufacturer.
